Economic consequences of molecular profiling for metastatic solid tumors. Cost-effectiveness of pazopanib (PAZ) versus sunitinib (SUN) as first-line treatment of metastatic renal cell carcinoma (mRCC) ...

This study used a cost-minimization analysis (CMA) to determine whether and to what extent student pharmacists’ interventions reduce out-of-pocket PDP costs for Medicare beneficiaries.

The ability to consistently get accurate cost estimates for new products and parts is elusive. Cost estimates are inherently imprecise, and the underlying drivers can change daily based on the price ...

Home administration of oral paclitaxel and encequidar is associated with potential cost savings for payers compared with clinic administration of intravenous chemotherapy in metastatic breast cancer ...